In addition to its clinical research activities, the AFIRM will create cooperative partnerships with industry to ensure that the technical innovations emerging from the research will transition rapidly into militarily relevant therapies and result in producible technologies, and ultimately will be translated into civilian population applications as well. The AFIRM will incorporate a close integration between basic science research and translational and clinical research in order to bring to practice effective regenerative medicine therapies.
The Wake Forest-University of Pittsburgh team has committed to develop
clinical therapies over the next five years that will focus on the
following five areas:
-- Burn repair
-- Wound healing without scarring
-- Craniofacial reconstruction
-- Limb reconstruction, regeneration or transplantation
-- Compartment syndrome, a condition related to inflammation after surgery
or injury that can lead to increased pressure, impaired blood flow,
nerve damage and muscle death
Collaborators for the Wake Forest-McGowan team include Organogenesis, Inc., Tufts University, Allegheny Singer Research Institute, the California Institute of Technology, Carnegie Mellon University, Georgia Institute of Technology, Intercytex, North Carolina State University, Oregon Medical Laser Center at Providence St. Vincent Medical Center, Pittsburgh Tissue Engineering Initiative, Rice University, the Stanford University School of Medicine, the University of California, Santa Barbara, the University of North Carolina, the University of Texas Health Science Center at Houston, the University of Wisconsin, and Vanderbilt University.
More than 50 technologies from the AFIRM team already have had a wide
impact on treatments for illness and injury. Researchers have launched more
than 10 clinical trials (three with the Arm
|SOURCE Organogenesis, Inc.|
Copyright©2008 PR Newswire.
All rights reserved